ReviewJournal of translational medicine2022
Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.
Review in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A global perspective on prognosis in acral and nonacral cutaneous melanoma: A systematic review and meta-analysis.Journal of the Chinese Medical Association : JCMA · 2026Pooled it
- Single-Cell Dissection of Tumor-Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SPP1Cell death & disease · 2026Article
- Predicting sentinel lymph node metastasis in melanoma patients: A machine learning-based predictive model.JAAD international · 2026Article
- Clinical characteristics and real-world survival in acral melanoma: experience from a comprehensive cancer center in Latin America.Frontiers in oncology · 2026Article
- Modeling rare melanoma subtypes: mechanisms, microenvironments and translational opportunities.Frontiers in oncology · 2026Review
- RAB37 Exerts a Context-Dependent Role in Cutaneous Melanoma Progression by Promoting Tumor Cell Proliferation and Being Associated with Favorable Immune Characteristics.Cancer management and research · 2026Article
- Ultrasonographic Analysis of Site-Specific Plantar Skin Thickness for Melanoma Staging and Excision.Clinical anatomy (New York, N.Y.) · 2026Article
- Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China.PloS one · 2026Article
- The gut-skin axis in melanoma: from microbial regulatory mechanisms to clinical translation for precision management.Frontiers in microbiology · 2026Review
- LASSO-Driven Selection of Biochemical and Clinical Markers for Primary Resistance to PD-1 Inhibitors in Metastatic Melanoma.Medicina (Kaunas, Lithuania) · 2025Article
- Association between Ki-67 and clinical outcomes in 324 Chinese patients with resectable acral melanoma.Scientific reports · 2025Article
- Histopathological Subtypes of Cutaneous Melanoma: Prognostic and Molecular Implications.Cureus · 2025Review
- Identification of two molecularly and prognostically distinct subtypes in acral melanoma using network prediction method.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review.Cancers · 2025Review
- A distinct subgroup with Schwann-like differentiation presents immune resistance and poor prognosis in plantar melanoma.Theranostics · 2025Article
- Gallic Acid-Modified Graphene Oxide Nanocomposites Based Photothermal-Chemotherapy Enhancing Melanoma Immunotherapy.International journal of nanomedicine · 2025Article
- Multivariate analysis and prediction model construction for distant metastasis of Acral Melanoma.American journal of cancer research · 2025Article
- Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.Signal transduction and targeted therapy · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acral melanoma (AM) has unique biology as an aggressive subtype of melanoma. It is a common subtype of melanoma in races with darker skin tones usually diagnosed at a later stage, thereby presenting a worse prognosis compared to cutaneous melanoma. The pathogenesis of acral melanoma differs from cutaneous melanoma, and trauma promotes its development. Compared to cutaneous melanomas, acral melanomas have a significantly lighter mutational burden with more copy number variants. Most acral melanomas are classified as triple wild-type. In contrast to cutaneous melanomas, acral melanomas have a suppressive immune microenvironment. Herein, we reviewed the clinical features, genetic variants, and immune microenvironmental characteristics of limbic melanomas to summarise their unique features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.